Cargando…

Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma

Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattinger, Claudia Maria, Salaroglio, Iris Chiara, Fantoni, Leonardo, Godel, Martina, Casotti, Chiara, Kopecka, Joanna, Scotlandi, Katia, Ibrahim, Toni, Riganti, Chiara, Serra, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821333/
https://www.ncbi.nlm.nih.gov/pubmed/36614241
http://dx.doi.org/10.3390/ijms24010799
_version_ 1784865671567376384
author Hattinger, Claudia Maria
Salaroglio, Iris Chiara
Fantoni, Leonardo
Godel, Martina
Casotti, Chiara
Kopecka, Joanna
Scotlandi, Katia
Ibrahim, Toni
Riganti, Chiara
Serra, Massimo
author_facet Hattinger, Claudia Maria
Salaroglio, Iris Chiara
Fantoni, Leonardo
Godel, Martina
Casotti, Chiara
Kopecka, Joanna
Scotlandi, Katia
Ibrahim, Toni
Riganti, Chiara
Serra, Massimo
author_sort Hattinger, Claudia Maria
collection PubMed
description Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved. This review is intended to give an overview on the immunotherapeutic treatments targeting, counteracting or exploiting the different immune cell compartments that are present in the HGOS tumor microenvironment. The principle at the basis of these strategies and the possible mechanisms that HGOS cells may use to escape these treatments are presented and discussed. Finally, a list of the currently ongoing immune-based trials in HGOS is provided, together with the results that have been obtained in recently completed clinical studies. The different strategies that are presently under investigation, which are generally aimed at abrogating the immune evasion of HGOS cells, will hopefully help to indicate new treatment protocols, leading to an improvement in the prognosis of patients with this tumor.
format Online
Article
Text
id pubmed-9821333
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98213332023-01-07 Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma Hattinger, Claudia Maria Salaroglio, Iris Chiara Fantoni, Leonardo Godel, Martina Casotti, Chiara Kopecka, Joanna Scotlandi, Katia Ibrahim, Toni Riganti, Chiara Serra, Massimo Int J Mol Sci Review Improving the prognosis and cure rate of HGOSs (high-grade osteosarcomas) is an absolute need. Immune-based treatment approaches have been increasingly taken into consideration, in particular for metastatic, relapsed and refractory HGOS patients, to ameliorate the clinical results currently achieved. This review is intended to give an overview on the immunotherapeutic treatments targeting, counteracting or exploiting the different immune cell compartments that are present in the HGOS tumor microenvironment. The principle at the basis of these strategies and the possible mechanisms that HGOS cells may use to escape these treatments are presented and discussed. Finally, a list of the currently ongoing immune-based trials in HGOS is provided, together with the results that have been obtained in recently completed clinical studies. The different strategies that are presently under investigation, which are generally aimed at abrogating the immune evasion of HGOS cells, will hopefully help to indicate new treatment protocols, leading to an improvement in the prognosis of patients with this tumor. MDPI 2023-01-02 /pmc/articles/PMC9821333/ /pubmed/36614241 http://dx.doi.org/10.3390/ijms24010799 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hattinger, Claudia Maria
Salaroglio, Iris Chiara
Fantoni, Leonardo
Godel, Martina
Casotti, Chiara
Kopecka, Joanna
Scotlandi, Katia
Ibrahim, Toni
Riganti, Chiara
Serra, Massimo
Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
title Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
title_full Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
title_fullStr Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
title_full_unstemmed Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
title_short Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma
title_sort strategies to overcome resistance to immune-based therapies in osteosarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821333/
https://www.ncbi.nlm.nih.gov/pubmed/36614241
http://dx.doi.org/10.3390/ijms24010799
work_keys_str_mv AT hattingerclaudiamaria strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT salaroglioirischiara strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT fantonileonardo strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT godelmartina strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT casottichiara strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT kopeckajoanna strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT scotlandikatia strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT ibrahimtoni strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT rigantichiara strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma
AT serramassimo strategiestoovercomeresistancetoimmunebasedtherapiesinosteosarcoma